Curriculum Vitae

Yan Zhou, M.D., Ph.D.

PERSONAL

**** ******* **

Houston, TX 77096, USA

E-mail: acb9qc@r.postjobfree.com

Phone: 832-***-****

US Citizen

ECFMG Certified (February 2007)

ABIM Board Certified (August 2012)

EDUCATION

9/97-10/00 Sun Yat-sen University of Medical Sciences, China

The University of Texas MD Anderson Cancer Center, USA

Ph. D. in Oncological Pharmacology

9/89-7/92 Sun Yat-sen University of Medical Sciences, China

M. S. in Clinical Pharmacology

9/83-7/89 Sun Yat-sen University of Medical Sciences, China

M. D. in Medical Science

PROFESSIONAL TRAINING

07/12-present Fellowship, Medical Oncology

(Graduating in 6/2014) Department of Internal Medicine,

Divisions of Hematology/Oncology

University of Texas Medical Branch at Galveston

07/09-06/12 Residency, Internal Medicine

Department of Internal Medicine, East Tennessee State University James H. Quillen

College of Medicine

01/01-08/04 Postdoctoral Fellow

Department of Molecular pathology, The University of Texas MD Anderson Cancer Center,

USA

07/97-12/00 Pre-doctoral Fellow

Sun Yat-sen University of Medical Sciences, China

Department of Clinical Investigation, the University of Texas MD

Anderson Cancer Center, USA

US CLINICAL EXPERIENCE

06/2012-present

The University of Texas Medical Branch at Galveston, Department of Internal Medicine,

Divisions of Hematology/Oncology

Oncology fellow

• Diagnosis, treatment and prevention of common solid tumors, benign hematologic

conditions and hematologic malignancies

1

2

• Outpatient experiences including fellow’s continuity clinic, faculty clinic, TDCJ continuity

oncology clinic as well as hematology clinic

• Inpatient services including inpatient hematology oncology wards, hematology consults and

oncology consult services

07/2009 -06/2012

East Tennessee State University, James H. Quillen College of Medicine, Department of

Internal Medicine

Medical Resident

• Comprehensive training in internal medicine

• Rotations at four different teaching hospitals including a VA Medical Center

01/2007– 05/2008 (EXTERNSHIP)

Internal Medicine, Michael E. DeBakey Veterans Affairs Medical Center in Houston

• Participate in a retrospective study with CPRS by collecting, organizing and analyzing data

while doing the externship

• Hands-on experiences in inpatient services and outpatient clinics

WORK EXPERIENCE

09/2008– 07/2009

East Tennessee State University, James H. Quillen College of Medicine, Department of

Internal Medicine

Research Associate

• Set up, organize, coordinate and direct a new research lab.

• Plan and participate in scientific research projects focusing on developing new strategies to

enhance therapeutic activity and overcome chemotherapy resistance in cholangiocarcinoma in vitro

and in vivo as well as the biochemical and molecular mechanisms of new anticancer agents.

08/1999– 09/2008

The University of Texas MD Anderson Cancer Center

Research Scientist, Postdoctoral and Pre-doctoral fellow

• Plan, organize, coordinate, direct, and participate in scientific research projects focusing on

evaluating potential therapeutic effects of several novel anticancer agents in vitro and in

vivo(different animal models) as well as the biochemical and molecular mechanisms of anticancer

drugs.

• Collaborate with clinics, developing new strategies to enhance therapeutic activity and

overcome drug resistance.

• Plan and supervise the training of technicians and other laboratory personnel

07/1992– 08/1999

Sun Yat-sen University of Medical Sciences, Guangzhou, China

Resident and Assistant Professor

• Clinical experiences: residency training and practice in medical oncology

• Clinical trial experiences: Sound experience in study design and data analysis of clinical

studies for different categories of new drugs (type I –V).

• Teaching experiences: train physicians and pharmacologists from all over the country as an

important member of the clinical trial institute for anticancer drugs authorized by SDA (the

government regulatory authority for Clinical trials in China).

2

• Research experience: investigation on biochemical and molecular mechanisms of

anticancer drugs.

AWARDS

• Outstanding Oral Presentation at the 2001 SCBA-Teaxs Annunal Symposium by SCBA-

Texas Chapter, USA, 2001

• Outstanding Teaching Study Award by Sun Yat-sen University of Medical Sciences, China,

1998

• Teaching Study Achievement Award by Guangdong Province, China, 1997

• “Top first Medical Student Fellowship” by Wenpeng LIN Couple (from USA)

Foundation, China, 1988

PUBLICATIONS

1. Garcia-Prieto C, Riaz Ahmed KB, Chen Z, Zhou Y et al., Effective Killing of Leukemia

Cells by the Natural Product OSW-1 through Disruption of Cellular Calcium Homeostasis.

J Biol Chem. 2013 Feb 1; 288(5):3240-50

2. Hu Y, Lu W, Chen G, Wang P, Chen Z, Zhou Y, et al., K ras(G12V) ransformation leads to

mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to

glycolysis. Cell Res. 2012 Feb; 22(2):399 412.

3. Zhou Y, Zhou Y, Shinggu K et al., Metabolic alterations in highly tumorigenic glioblastoma

cells: preference for hypoxia and high dependency on glycolysis. J. Bio. Chem. 2011; 286:

328**-*****.

4. Pelicano H, Lu W, Zhou Y; et al., Mitochondrial dysfunction and reactive oxygen species

imbalance promote breast cancer cell motility through a CXCL14-mediated mechanism .

Cancer Research. 2009; 69(6):2375-83.

5. Trachootham D; Zhang H; Zhang W; Feng L; Du M; Zhou Y, et al., Effective elimination of

fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood.

2008;112(5):1912-22.

Leng X, Lin H, Ding T, Wang Y, Wu Y, Klumpp S, Sun T, Zhou Y, et al, Lipocalin 2 is

6.

required for BCR ABL induced tumorigenesis. Oncogene. 2008 16; 27(47): 6110 9. 2008

7. Trachootham D, Zhou Y, Zhang H, et al., Selective killing of oncogenically transformed

cells through a ROS mediated mechanism by b-phenylethyl isothiocyanate. Cancer Cell.

2006; 10(3): 241–252.

8. Carew JS, Zhou Y and Huang P: Oxidative stress, cell proliferation, and apoptosis. In:

Oxidative Stress, Disease and Cancer, Ed: Singh K. K, Imperial College Press (London),

Ch 9, pp309-332, 2006.

9. Zhou Y, Garcia-Prieto C, Carney DA, et al., OSW-1: a natural compound with potent

anticancer activity and a novel mechanism of action. J Natl Cancer Inst. 2005 Dec 7;

97(23):1781-5.

10. Hu Y, Rosen DG, Zhou Y, et al., Mitochondrial Manganese-Superoxide Dismutase

Expression in Ovarian Cancer: ROLE IN CELL PROLIFERATION AND

RESPONSE TO OXIDATIVE STRESS. J. Biol. Chem. 2005 Nov 25; 280(47): 39485 –

39492.

11. Xu RH, Pelicano H, Zhou Y, et al., Inhibition of glycolysis in cancer cells: a novel strategy

to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia,

Cancer Res. 2005 Jan 15; 65(2):613-21.

3

4

12. Carew JS, Zhou Y, Albitar M, et al., Mitochondrial DNA mutations in primary leukemia

cells after chemotherapy: clinical significance and therapeutic implications. Leukemia.

2003 Aug; 17 (8):1437-1447.

13. Pelicano H, Feng L, Zhou Y, et al., “Inhibition of Mitochondrial Respiration: a noval

strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen

species-mediated mechanism”, J. Biol. Chem. 2003 Sep 26; 278(39):37832-9.

14. Zhou Y, Hileman EO, Plunkett W, et al., “Free radical stress in chronic lymphocytic

leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents”,

Blood, 2003 May 15; 101(10): 4098 - 4104.

15. Zhou Y, Achanta G, Pelicano H, et al., “Action of (E)-2’-Deoxy-2’-(fluoro-methylene)-

cytidine on DNA Metabolism: Incorporation, Excision, and Cellular Response”, Mol

Pharmocology, 2002 Jan; 61(1): 222-9.

16. Cai KH, Zheng WH, Zhou Y, et al., “Analysis Method and Pharmacokinetics Studies of

Simvastatin in Plasma”, Chinese Journal of Analytical Chemistry 1999; 27(11): 1254-7.

17. Zhou Y, Cai KH, Zeng GX, et al., “Pharmacokinetics and Bioavailability of Simvastatin in

10 Chinese Young Men”, Acta Pharmacologica Sinica, 1999; 20(1):95-6.

18. Zhou Y, Zhao XL. “Determination of Acetyltransferase Activity of Human Mammary

Tumor MCF-7 Cells in Culture”, Foreign Medical Sciences(Cancer Section),

1998;25(5):79.

19. Zhou Y, Huang LH, Zeng GX, et al.,“Bioavailability of Domestic Dispersing Tablet of

Azithromycin in Chinese men”, Chinese Journal of Modern Applied Pharmacy,

1998;8(15)(Sup):15-6.

20. Zhou Y, Zhao XL, Zeng GX, et al.,“Affecting Factors of the Hemostasis Effect of Thrombin

on Upper Digestive Tract Bleeding”, Chinese Pharmacological Bulletin, 1998;14(2): 127-

9.

21. Zhao XL, Huang LH, Feng X and Zhou Y. “Comparison on Clinical Pharmacokinetics of

Roxithromycin and Erythromycin Estolate”, Chinese New Drugs Journal, 1998; 7(2):134-

137.

22. Zhao XL, He JY, Huang M, Z hou Y. “Phase I Clinical Trial of Domestic Lomefloxacin”,

Chinese Journal of Clinical Pharmacology, 1994; 10(2): 82-86.

23. Zhou Y and Zhao XL. “Mechanism of Acetylation Rate Elevation at Mammary Tumor-

bearing Status”, Chinese J. of Cancer, 1994; 12(6): 494-496.

PROFESSIONAL CONFERENCES

1. Zhou Y, R.B Fritz et al: "Potentiation of cisplatin cytotoxicity by beta-phenylethyl

isothiocyanate in cholangiocarcinoma cells." (Abst # 1841) The Liver Meeting 2009

(AASLD's 60th Annual Meeting). October 30 - November 3, 2009, Boston, MA.

2. Zhou Y, R.B Fritz et al: “OSW-1 induces calcium-dependent apoptosis in

cholangiocarcinoma (Abst # 1842).” The Liver Meeting 2009 (AASLD's 60th Annual

Meeting). October 30 - November 3, 2009, Boston, MA.

3. Zhou Y, Garcia-Prieto C, Carney DA, et al.; “OSW-1, A Potent Natural Anticancer Agent

Inducing Apoptosis with Unique Action Mechanism”, 95th American Association for Cancer

Research Annual Meeting, Orlando, Florida, Mar 27-31, 2004.

4

4. Pelicano H, Zhou Y, et al., “Enhancement Dug-induced Apoptosis in Cancer Cells Through

an ROS-mediated Mechanism”, 94th American Association for Cancer Research Annual

Meeting, Washington, DC, July 11-14, 2003.

5. Zhou Y, Hileman EO, Plunkett W, et al., “Correlation between Superoxide Generation and

Cellular Response to Anticancer Agent 2-Methoxyestradiol in Chronic Lymphocytic

Leukemia Cells”, 93rd American Association for Cancer Research Annual Meeting, San

Francisco, CA, April 6-10, 2002.

6. Zhou Y, Achanta G, Pelicano H, et al.., “Action of (E)-2’-Deoxy-2’-(fluoromethylene)-

cytidine on DNA Metabolism: Incorporation, Excision, and Cellular Response”, the 2001

SCBA-Texas Annual Symposium, Houston, 2001.

7. Zhou Y, Achanta G, Pelicano H, et al.., “Action of (E)-2’-Deoxy-2’-(fluoromethylene)-

cytidine on DNA Metabolism: Incorporation, Excision, and Cellular Response”, 92nd

American Association for Cancer Research Annual Meeting, New Orleans, LA, Mar 24-28,

2001.

8. Zhou Y, Zhao XL. “Determination of Acetyltransferase Activity of Human Breast Cancer

MCF-7 Cells in Culture”, the Seventh Meeting on Pharmacology and Chemotherapy of

Oncology, Taian, China, 1998.

9. Zhou Y, Cai KH, et al.,“Pharmacokinetics and Bioavailability of Simvastatin in 10 Chinese

Young Men”, ‘98 China-Japan Joint Meeting on Pharmacology, Hunan, China, 1998.

10. Zhou Y and Zhao XL. “Comparison of Steady State Plasma Concentration of Ibuprofen of

Two Kinds of Preparations”, the 6th Meeting of China on Clinical Pharmacology, Chengdu,

China, 1996.

11. Zhou Y and Zhao XL. “Mechanism of Acetylation Rate Elevation at Mammary Tumor-

bearing Status”, the forth Meeting on Pharmacology and Chemotherapy of Oncology,

Zhengzhou, China, 1992.

12. Zhou Y and Zhao XL “Mechanism of Acetylation Rate Elevation at Mammary Tumor-

bearing Status”, the Third China-Japan Joint Meeting on Pharmacology, Beijing, China,

1992.

LANGUAGES

Fluent in English and Chinese (Mandarin and Cantonese)

REFRENCES

1. Guillermo Garcia-Manero, M.D. Professor, Chief, Section of Myelodysplastic

Syndromes, Department of Leukemia, Division of Cancer Medicine, the University of Texas

MD Anderson Cancer Center, Phone: 713-***-****, Email: acb9qc@r.postjobfree.com

2. Gene D. LeSage, M.D., FACP, Professor, Co-Director, Internal Medicine Clerkship,

Division of Gastroenterology, Department of Internal Medicine, East Tennessee State

University 's Quillen College of Medicine, Phone: 423-***-****, E-mail: acb9qc@r.postjobfree.com

3. Mohsen Ghadimi-Mahani, MD. Assistant Professor, Division of

Hematology/Oncology, Department of Internal Medicine, the University of Texas Medical

Branch at Galveston, Phone: 409-***-****, Email: acb9qc@r.postjobfree.com

5

Contact this candidate